➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Moodys
McKinsey
Express Scripts
AstraZeneca

Last Updated: December 2, 2020

DrugPatentWatch Database Preview

Patent: 8,445,637

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,445,637
Title:SPARC binding peptides and uses thereof
Abstract: Disclosed are SPARC and albumin binding peptides for the targeting of disease sites, such as tumors, with therapeutic and diagnostic agents In particular, compositions comprising SPARC binding peptide--Antibody Fc domain fusion proteins and methods of their use are disclosed.
Inventor(s): Trieu; Vuong (Agoura Hills, CA)
Assignee: Abraxis BioScience, LLC (Los Angeles, CA)
Application Number:13/132,274
Patent Claims:see list of patent claims

Details for Patent 8,445,637

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial Abraxis BioScience, LLC (Los Angeles, CA) 2028-12-05 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Abraxis BioScience, LLC (Los Angeles, CA) 2028-12-05 RX Orphan search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Abraxis BioScience, LLC (Los Angeles, CA) 2028-12-05 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Abraxis BioScience, LLC (Los Angeles, CA) 2028-12-05 RX search
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial Abraxis BioScience, LLC (Los Angeles, CA) 2028-12-05 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 8,445,637

Country Patent Number Estimated Expiration
South Africa 201104122   Start Trial
World Intellectual Property Organization (WIPO) 2010065954   Start Trial
World Intellectual Property Organization (WIPO) 2010065969   Start Trial
United States of America 10053504   Start Trial
United States of America 2012014954   Start Trial
United States of America 2012039801   Start Trial
United States of America 2013315823   Start Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Baxter
Boehringer Ingelheim
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.